trending Market Intelligence /marketintelligence/en/news-insights/trending/VHvPtbBO3-vIDuOVSefPwA2 content esgSubNav
In This List

Fluidigm appoints 2 directors

Case Study

Identifying PPE Suppliers During the Pandemic

Blog

Highlighting the Top Regional Aftermarket Research Brokers by Sector Coverage

Video

COVID-19 Impact & Recovery: Healthcare Outlook for H2 2021

Blog

Corporate Credit Risk Trends in Developing Markets: A Loss Given Default (LGD) Perspective


Fluidigm appoints 2 directors

Fluidigm Corp. appointed Nicolas Barthelemy and Carlos Paya to its board of directors.

From 2014 to February 2017, Barthelemy served as president and CEO of Biotheranostics, a privately held molecular diagnostics company.

Paya is president, CEO and director of Immune Design Corp., a clinical-stage immunotherapy company focused on oncology.